GRIFOLS | GRF - Selling And Administration Expenses


GRIFOLS reported EUR289M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Alcon AG USD 882M 19M Mar/2026
Amadeus IT EUR 497.5M 206.6M Mar/2025
Amarin USD 18.97M 1.03M Dec/2025
argenx SE USD 417M 62M Jun/2026
AstraZeneca USD 5.8B 735M Jun/2026
Bayer EUR 3.7B 356M Mar/2026
Cie Automotive EUR 315.66M 28.06M Dec/2024
Demant DKK 6.09B 135M Dec/2025
Ence Energia y Celulosa EUR 29.1M 2M Sep/2024
Essilor EUR 5.75B 139M Jun/2026
Ferrovial EUR 906M 52M Dec/2024
Fresenius EUR 819M 143M Dec/2025
Fresenius Medical Care EUR 749M 36M Mar/2026
Genmab DKK 208M 60M Dec/2025
GlaxoSmithKline GBP 2.19B 75M Jun/2026
GRIFOLS EUR 289M 8M Jun/2026
Hikma Pharmaceutical USD 288M 149M Dec/2025
Inditex EUR 2.51B 7.98B Jan/2025
Lakefront Biotherapeutics EUR 35.5M 8.91M Mar/2026
Merck EUR 1.52B 80M Mar/2026
Novartis USD 3.24B 101M Jun/2026
Philips EUR 1.21B 23M Jun/2026
Roche Holding CHF 6.37B 908M Jun/2026
Sanofi EUR 2.63B 307M Jun/2026
Smith & Nephew USD 1.45B 29M Jun/2026
UCB EUR 1.47B 193M Dec/2025
Viscofan EUR 72.59M 4.52M Mar/2025